Show simple item record

dc.contributor.authorFleeman, N
dc.contributor.authorPayne, K
dc.contributor.authorNewman, W
dc.contributor.authorHowell, Sacha J
dc.contributor.authorBoland, A
dc.contributor.authorOyee, J
dc.contributor.authorSaborido, C
dc.contributor.authorSantander, A
dc.contributor.authorDickson, R
dc.date.accessioned2013-09-25T11:58:28Z
dc.date.available2013-09-25T11:58:28Z
dc.date.issued2013
dc.identifier.citationAre health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen 2013, 10 (6):601 Personalized Medicineen_GB
dc.identifier.issn1741-0541
dc.identifier.issn1744-828X
dc.identifier.doi10.2217/pme.13.60
dc.identifier.urihttp://hdl.handle.net/10541/302259
dc.language.isoenen
dc.relation.urlhttp://www.futuremedicine.com/doi/abs/10.2217/pme.13.60en_GB
dc.rightsArchived with thanks to Personalized Medicineen_GB
dc.titleAre health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen.en
dc.typeArticleen
dc.identifier.journalPersonalized Medicineen_GB


This item appears in the following Collection(s)

Show simple item record